NORWAY - Algeta raises NOK 250m in IPO
Algeta, Norwegian Cancer therepeutics successfully closed its IPO at a gross proceeds (before over-allotment) of NOK 250m. The offering was more than twice over-subscribed and was priced in the upper half of NOK 47 per share. The offering took place in conjunction with Algeta's listing on the Oslo stock exchange, and the shares are expected to begin to trade today (27 March).
More on Exits
Livingbridge sells Broadstone to ICG
Broadstone generated EBITDA of £646,000 from revenues of £9.5m in the year ending on 30 June 2019
Polaris to launch sale of ProData Consult in 2021 – Mergermarket
Asset is reportedly due to come to market in 2021, with the sale process most likely starting in H1
CBPE hires Arma to sell Xceptor
Xceptor recorded group revenues of £27m and EBITDA of £10.8m for the year ending on 31 July 2020
Abénex backs Squad MBO, Apax exits
Apax Partners Development (formerly EPF Partners) invested around €10m in the cybersecurity firm in 2017
Latest News
PE-backed Helgstrand Dressage merges with Ludger Beerbaum Stables
Waterland-backed Danish company Helgstrand Dressage has acquired and merged with equestrian show jumping business Ludger Beerbaum Stables.
Zefyr Invest acquires Bramidan from Blue Equity
GP is deploying equity from Zefyr Invest III, and Bramidan is its third acquisition from the vehicle
Merieux Equity buys Plantex
GP invests in the company via Mérieux Participations 3, which closed on €377m in January 2020
Carlyle-backed Hurst Point acquires Hawksmoor
Hurst Point Group was established in 2019 to facilitate investment by Carlyle in UK wealth management